Mobile Menu

3D Genetics, EpiSwitch™️ and Clinical Translation: Development of Liquid Biopsy for Diffuse large B-cell lymphoma prognosis and benchmarking it against digital PCR gold standards

When: March 24, 2021 Time: 3:00 pm

Chromatin exists as a non-linear, “three-dimensional” structure in the nuclear space, and refers to the complex of DNA and proteins and how they are packaged within a cell. This high level of organisation puts another layer of regulation and control on an already complicated system.

Epigenetics can refer to DNA methylation, histone modifications, non-coding RNA, and Chromosome Conformation Signatures (CCSs), which is the highest framework level of epigenetic regulation. These signatures can be used to identify disease states and for clinical diagnostics.

Using two studies developed with pharma partners, this presentation from Ewan Hunter (Chief Data Officer, Oxford Biodynamics) describes the EpiSwitch technology and how it was utilised to develop a liquid biopsy for diffuse large B-cell lymphoma (DLBCL) prognosis whilst conforming to digital PCR gold standards.

What you will take away from this webinar:

  • How chromosome conformation signatures can be used as biomarkers
  • How to go from whole blood classifications to clinical outcomes
  • How a blood-based assay was created to identify subtypes of DLBCL

This webinar has been made possible with the kind support of our partner, Agilent.

Webinar Registration


Ewan Hunter Ewan Hunter, Director, Institute of Computational Biology, Oxford Biodynamics

More on these topics

Chromatin / Liquid Biopsy

Article Search